114 related articles for article (PubMed ID: 9755434)
1. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
Bohdiewicz PJ
J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
[TBL] [Abstract][Full Text] [Related]
2. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
3. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
4. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management.
Corman ML; Galandiuk S; Block GE; Prager ED; Weiner GJ; Kahn D; Abdel-Nabi H; Mitchell EP; Pascucci VL; Maroli AN
Dis Colon Rectum; 1994 Feb; 37(2):129-37. PubMed ID: 8306832
[TBL] [Abstract][Full Text] [Related]
5. Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
Silberstein EB; Saeks E
Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891
[TBL] [Abstract][Full Text] [Related]
6. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
Low RN; Carter WD; Saleh F; Sigeti JS
Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
[TBL] [Abstract][Full Text] [Related]
8. Oncoscint for detection of disseminated colorectal and ovarian cancer.
Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
[No Abstract] [Full Text] [Related]
9. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
Gallup DG
Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
[No Abstract] [Full Text] [Related]
10. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
Neal CE; Johnson DL; Cornwell VL; Markwell S
Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
[TBL] [Abstract][Full Text] [Related]
11. OncoScint image atlas.
Maguire RT
Targeted Diagn Ther; 1992; 6():141-75. PubMed ID: 1576344
[No Abstract] [Full Text] [Related]
12. Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
Surwit EA
Targeted Diagn Ther; 1992; 6():125-40. PubMed ID: 1576343
[No Abstract] [Full Text] [Related]
13. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
14. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
[TBL] [Abstract][Full Text] [Related]
15. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response.
Winzelberg GG; Grossman SJ; Rizk S; Joyce JM; Hill JB; Atkinson DP; Sudina K; Anderson K; McElwain D; Jones AM
Cancer; 1992 Apr; 69(7):1656-63. PubMed ID: 1551051
[TBL] [Abstract][Full Text] [Related]
16. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in ovarian and prostate cancer.
Neal CE; Swenson LC; Fanning J; Texter JH
Semin Nucl Med; 1993 Apr; 23(2):114-26. PubMed ID: 8511599
[TBL] [Abstract][Full Text] [Related]
18. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.
Bohdiewicz PJ; Scott GC; Juni JE; Fink-Bennett D; Wilner F; Nagle C; Dworkin HJ
Clin Nucl Med; 1995 Mar; 20(3):230-6. PubMed ID: 7750217
[TBL] [Abstract][Full Text] [Related]
19. Challenges in immunoscintigraphy of ovarian cancer.
Kim EE; Kasi LP
Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
[No Abstract] [Full Text] [Related]
20. [Immunoscintigraphy of prostatic cancer].
Aliaev IuG; Vinarov AZ; Rapoport LM; Bezrukov EA; Butnaru DV
Urologiia; 2006; (4):67-9. PubMed ID: 17058687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
